Thermo Fisher Scientific's $3.2 Billion Bond Sale Criticized

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Analysts at one investment firm are already criticizing Thermo Fisher’s $3.2 billion bond offering announced yesterday, saying the move will likely increase the company’s debt load to risky levels. The scathing report was issued this morning by Gimme Credit, a fixed-income research firm, and followed news that Fitch Ratings had lowered the Waltham medical device giant’s credit rating by a notch to BBB and that Moody’s Investors Service said it probably will do the same once the bond sale closes. The Gimme Credit report questioned Thermo Fisher’s “ever-increasing appetite for debt” as the company works to raise the capital needed to complete its $13.6 billion acquisition of Carlsbad, Calif.-based Life Technologies.

Help employers find you! Check out all the jobs and post your resume.

Back to news